triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer
February 2002
The FDA has approved the long-acting form of triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer.
This specific topic you are searching for was not covered in the newsletter. In the process of putting together the newsletters, the editorial staff can only pick a limited number of topics. This forces us to cut topics that are still informative and useful. As an extra service to our subscribers we are offering the Detail-Document.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote